A CLDN18.2‐Targeted Nanoplatform Manipulates Magnetic Hyperthermia Spatiotemporally for Synergistic Immunotherapy in Gastric Cancer
Abstract Precision treatment of gastric cancer requires specific biomarkers, and CLDN18.2 emerges as a promising target for patients’ stratification and therapeutic guidance. In 563 cases, 54.4% of patients are identified as CLDN18.2‐positive, with CLDN18.2 expression negatively correlated with immu...
Saved in:
| Main Authors: | Xueying Wang, Hui Hui, Jing Han, Ting Guo, Yiding Wang, Lin Meng, Cong Chen, Jie He, Xiaoyong Guo, Fuyu Zhong, Hong Du, Jie Tian, Xiaofang Xing, Yang Du, Jiafu Ji |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202413913 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pan-cancer analysis of CLDN18.2 shed new insights on the targeted therapy of upper gastrointestinal tract cancers
by: Jun Wu, et al.
Published: (2024-11-01) -
Complete remission of recurrent gastric cancer in a young female patient through CLDN18.2-targeted therapy (LM302) and metastatic ovarian tumor resection: a case report of refractory disease overcoming chemotherapy and immunotherapy resistance
by: Muyang Chen, et al.
Published: (2025-08-01) -
Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody
by: Hayat Bähr-Mahmud, et al.
Published: (2023-12-01) -
Utility of 131I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate Approach in Mouse Models
by: Liu Y, et al.
Published: (2025-01-01) -
Comprehensive analysis reveals CLDN9 is a new biomarker in human cancers and immunotherapeutic target for glioblastoma multiforme
by: Yuanyuan Zhu, et al.
Published: (2025-06-01)